title: Liver transplantation in primary biliary cirrhosis: risk assessment and 11-year follow-up.
abstract: OBJECTIVE
  Liver transplantation (LTx) is the only established treatment in patients with end-stage primary biliary cirrhosis (PBC). Although short-term survival after LTx in this group of patients is usually good, few data exist on the long-term survival. The optimal timing of transplantation is difficult. Thus, the aims of this study were to assess the long-term survival of patients with PBC after LTx and to identify potential predictive factors for a positive outcome.
  
  
  METHODS
  Survival of 28 patients with PBC who underwent LTx between 1985 and July 1999 in a single center was studied by Kaplan-Meier analysis and was compared to predicted survival without LTx using established prognostic models for PBC, the Mayo and European risk scores. Potential prognostic parameters obtained before LTx were tested for correlation to survival. Rates of bone fractures as markers of hepatic osteodystrophy were compared before and after LTx.
  
  
  RESULTS
  Median follow-up after LTx was 90 months with a maximum of 140 months. Actuarial survival of patients with PBC was 89% after 1, 5, and 10 years and was significantly better than estimated survival without LTx after 1-7 years as calculated by the Mayo and European risk scores. Of several parameters tested, only serum bilirubin and the prognostic scores, but no other liver function tests obtained immediately prior to transplantation were significantly correlated with survival after LTx. The duration of intensive care after LTx was not associated with any parameters obtained before LTx. Bone fractures were diagnosed in 43% of patients of whom the vast majority were osteopenic before LTx as determined by osteodensitometry.
  
  
  CONCLUSIONS
  Long-term survival of a well-defined group of patients with PBC was excellent after LTx and was inversely correlated with preoperative serum bilirubin levels as well as Mayo and European risk scores.
authors.affiliation: Department of Internal Medicine II, Klinikum Grosshadern, University of Munich, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Rust
authors.forename: H
authors.initials: H
authors.lastname: Rau
authors.forename: A L
authors.initials: AL
authors.lastname: Gerbes
authors.forename: G R
authors.initials: GR
authors.lastname: Pape
authors.forename: M
authors.initials: M
authors.lastname: Haller
authors.forename: H
authors.initials: H
authors.lastname: Krämling
authors.forename: F W
authors.initials: FW
authors.lastname: Schildberg
authors.forename: G
authors.initials: G
authors.lastname: Paumgartner
authors.forename: U
authors.initials: U
authors.lastname: Beuers
mesh_terms: D000328:Adult; D000368:Aged; D001663:Bilirubin / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D001663:Bilirubin